Nasdaq · CIK 0001789769
TIL Instil Bio, Inc.
Insider trading from SEC Form 4. Last filing Jun 12, 2026. Close $6.74 on Oct 9, 2026, +3% from the 52-week low and -68% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
TILOct 9, 2026 · close 6.74
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Instil Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Sandeep Laumas CFO and CBO sell | $702k 30,000 shares | -100% | - |
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Gwendolyn Binder director | AGrant or award Stock Option (Right to Buy)derivative | +6,500 | $0.00 | $0 | 6,500 | Jun 12, 2026 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | MOption exercise Common Stock | +17,000 | $11.60 | $197k | 17,000 | Sep 12, 2025 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | MOption exercise Common Stock | +13,000 | $12.68 | $165k | 30,000 | Sep 12, 2025 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | SOpen-market sale Common Stock | -17,539 | $23.04 | $404k | 12,461 | Sep 12, 2025 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | SOpen-market sale Common Stock | -12,461 | $23.88 | $298k | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | MOption exercise Employee Stock Option (right to buy)derivative | -17,000 | $0.00 | $0 | 17,000 | Sep 12, 2025 |
| Sep 10, 2025 | Sandeep Laumas CFO and CBO | MOption exercise Employee Stock Option (right to buy)derivative | -13,000 | $0.00 | $0 | 30,000 | Sep 12, 2025 |
| May 28, 2025 | Gwendolyn Binder director | AGrant or award Stock Option (Right to Buy)derivative | +6,500 | $0.00 | $0 | 6,500 | May 29, 2025 |
| May 28, 2025 | Neil W Gibson director | AGrant or award Stock Option (Right to Buy)derivative | +6,500 | $0.00 | $0 | 6,500 | May 29, 2025 |
| May 28, 2025 | R Kent McGaughy Jr director | AGrant or award Stock Option (Right to Buy)derivative | +6,500 | $0.00 | $0 | 6,500 | May 29, 2025 |
| May 28, 2025 | George Matcham director | AGrant or award Stock Option (Right to Buy)derivative | +6,500 | $0.00 | $0 | 6,500 | May 29, 2025 |
| Apr 25, 2025 | Bronson Crouch CEO and Chairman | AGrant or award Employee Stock Option (right to buy)derivative | +105,157 | $0.00 | $0 | 105,157 | Apr 28, 2025 |
| Apr 25, 2025 | Sandeep Laumas CFO and CBO | AGrant or award Employee Stock Option (right to buy)derivative | +44,851 | $0.00 | $0 | 44,851 | Apr 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Gwendolyn Binderpresident, officer, director
- Bronson CrouchCEO and Chairman
- Neil W Gibsondirector
- Sandeep LaumasCFO and CBO
- George Matchamdirector
- R Kent McGaughy Jrdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.